Last reviewed · How we verify
Bravelle
At a glance
| Generic name | Bravelle |
|---|---|
| Also known as | urinary FSH, Bravelle®, Urofollitropin, purified form of follicle-stimulating hormone (FSH) |
| Sponsor | Instituto de Investigacion Sanitaria La Fe |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial (PHASE4)
- Continuous Double Ovarian Stimulation. (PHASE4)
- Hormone Evaluation in Artificial Reproductive Technology (NA)
- Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study (PHASE4)
- C677T Methylenetetrahydrofolate Reductase Mutation
- Needle-Free Injections of Gonadotropins for Superovulation (NA)
- Single Dose FSH-GEX™ in Healthy Volunteers (PHASE1)
- Multiple Dose FSH-GEX(TM) in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bravelle CI brief — competitive landscape report
- Bravelle updates RSS · CI watch RSS
- Instituto de Investigacion Sanitaria La Fe portfolio CI